Scisparc Ltd Surges in Pre-Market Trading
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 26 Nov 25
Source: 6-K
Scisparc Ltd is experiencing a significant pre-market price increase of 34.02%. This surge is attributed to strong market momentum, with the Nasdaq-100 and S&P 500 both showing positive gains of 0.25% and 0.15%, respectively.
The technical indicator shows that Scisparc Ltd has crossed above its 20-day simple moving average (SMA), indicating bullish sentiment among investors. This technical strength often attracts further buying interest, contributing to the stock's upward movement.
Overall, the combination of favorable market conditions and technical indicators suggests a positive outlook for Scisparc Ltd in the near term.
Analyst Views on SPRC
About SPRC
Scisparc Ltd, former Therapix Biosciences Ltd is a Israel-based pharmaceutical company commited into creating and enhancing technologies and assets based on cannabinoid pharmaceuticals. The company is engaged in drug development programs based on repurposing a cannabinoid (Dronabinol): THX-110 for the treatment of Tourette syndrome (TS), for the treatment of Obstructive Sleep Apnea (OSA), and the treatment of Pain; THX-130 for the treatment of Mild Cognitive Impairment (MCI) and Traumatic Brain Injury (TBI); THX-150 for the treatment of infectious diseases; and THX-160 for the treatment of pain.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
